{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:35:29Z","timestamp":1759538129747,"version":"build-2065373602"},"reference-count":68,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA186107","CA49449","CA167552","AR075117"],"award-info":[{"award-number":["CA186107","CA49449","CA167552","AR075117"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["7-21-JDFM-005"],"award-info":[{"award-number":["7-21-JDFM-005"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Diabetes"},{"DOI":"10.13039\/100000062","name":"Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK138036"],"award-info":[{"award-number":["R01DK138036"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20326"],"award-info":[{"award-number":["DB-2020C2-20326"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["5U01FD007213"],"award-info":[{"award-number":["5U01FD007213"]}],"id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Current osteoporosis risk stratification relies on clinical factors and bone mineral density alone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine if osteocalcin, c-terminal cross-linking telopeptide of type 1 collagen, sclerostin, and bicarbonate (\u201cbone-related biomarkers\u201d) are associated with future fracture risk or improve risk stratification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Nested, matched case-control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Longitudinal cohorts of health care workers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Individuals with and without hip fracture in the Nurses\u2019 Health Study I and the Health Professionals Follow-up Study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measure<\/jats:title>\n                  <jats:p>Hip fracture.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 642 women in Nurses\u2019 Health Study I (mean age, 70.3 years; 29% with osteoporosis), we found no consistent associations between bone-related biomarkers and incident hip fracture, and addition of biomarkers to clinical models predicting incident hip fracture did not improve model fit. Among 586 men in Health Professionals Follow-up Study (mean age, 63.8 years; &amp;lt;1% with osteoporosis), higher levels of osteocalcin (odds ratio, 0.37 [95% CI, 0.13-1.04] for quintile 5 vs quintile 1; P for trend = .02) and sclerostin (odds ratio, 0.22 [95% CI, 0.09-0.54] for quintile 5 vs quintile 1; P for trend &amp;lt; .001) were associated with lower risk of hip fracture; however, addition of sclerostin to clinical models predicting incident hip fracture provided limited additional predictive value.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Osteocalcin, c-terminal cross-linking telopeptide of type 1 collagen, sclerostin, and bicarbonate were not associated with incident hip fracture among older, predominantly White women. Osteocalcin and sclerostin were associated with hip fracture among men but did not meaningfully improve the predictive accuracy of models based on clinical risk factors alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf148","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T18:24:49Z","timestamp":1757528689000},"source":"Crossref","is-referenced-by-count":0,"title":["The Association of Bone-related Biomarkers With Incident Hip Fracture: A Nested Case-control Study"],"prefix":"10.1210","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-2049","authenticated-orcid":false,"given":"Sara J","family":"Cromer","sequence":"first","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-0839","authenticated-orcid":false,"given":"Elaine W","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Epidemiology, Harvard T. H. Chan School of Public Health , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary C","family":"Curhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Epidemiology, Harvard T. H. Chan School of Public Health , Boston, MA 02115 ,","place":["USA"]},{"name":"Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M","family":"Paik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]},{"name":"Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]},{"name":"Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital , Boston, MA 02115 ,","place":["USA"]},{"name":"New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System , Boston, MA 02130 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"issue":"8","key":"2025100307131636400_bvaf148-B1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s001980070064","article-title":"Long-term risk of osteoporotic fracture in Malm\u00f6","volume":"11","author":"Kanis","year":"2000","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025100307131636400_bvaf148-B2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s001980170152","article-title":"Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women","volume":"12","author":"Doherty","year":"2001","journal-title":"Osteoporos Int"},{"issue":"12","key":"2025100307131636400_bvaf148-B3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","article-title":"Bone density and fracture risk in men","volume":"13","author":"Melton","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025100307131636400_bvaf148-B4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1359\/jbmr.070315","article-title":"Residual lifetime risk of fractures in women and men1","volume":"22","author":"Nguyen","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"14","key":"2025100307131636400_bvaf148-B5","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2009.1462","article-title":"Incidence and mortality of hip fractures in the United States","volume":"302","author":"Brauer","year":"2009","journal-title":"JAMA"},{"issue":"10","key":"2025100307131636400_bvaf148-B6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","article-title":"Excess mortality following hip fracture: a systematic epidemiological review","volume":"20","author":"Abrahamsen","year":"2009","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025100307131636400_bvaf148-B7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-023-06907-3","article-title":"Global burden of hip fracture: the global burden of disease study","volume":"35","author":"Feng","year":"2024","journal-title":"Osteoporos Int"},{"key":"2025100307131636400_bvaf148-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"2025100307131636400_bvaf148-B9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025100307131636400_bvaf148-B10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","article-title":"Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society","volume":"28","year":"2021","journal-title":"Menopause"},{"issue":"10","key":"2025100307131636400_bvaf148-B11","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025100307131636400_bvaf148-B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025100307131636400_bvaf148-B13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX\u2122 and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"author":"Kanis","key":"2025100307131636400_bvaf148-B14"},{"issue":"3","key":"2025100307131636400_bvaf148-B15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03256280","article-title":"Biomarkers for osteoporosis management","volume":"12","author":"Garnero","year":"2008","journal-title":"Mol Diag Ther"},{"issue":"4","key":"2025100307131636400_bvaf148-B16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40291-017-0272-1","article-title":"The utility of biomarkers in osteoporosis management","volume":"21","author":"Garnero","year":"2017","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"2025100307131636400_bvaf148-B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3803\/EnM.2020.35.1.55","article-title":"Potential biomarkers to improve the prediction of osteoporotic fractures","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"3","key":"2025100307131636400_bvaf148-B18","first-page":"719","article-title":"Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study1","volume":"82","author":"Vergnaud","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025100307131636400_bvaf148-B19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00223-015-0070-x","article-title":"Advanced age, high \u03b2-CTX levels, and impaired renal function are independent risk factors for all-cause one-year mortality in hip fracture patients","volume":"98","author":"Gulin","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2025100307131636400_bvaf148-B20","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-3419","article-title":"Serum sclerostin and risk of hip fracture in older Caucasian women","volume":"97","author":"Arasu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025100307131636400_bvaf148-B21","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00198-014-3006-9","article-title":"The effect of supplementation with alkaline potassium salts on bone metabolism: a meta-analysis","volume":"26","author":"Lambert","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025100307131636400_bvaf148-B22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bone.2008.09.007","article-title":"Alkaline mineral water lowers bone resorption even in calcium sufficiency: alkaline mineral water and bone metabolism","volume":"44","author":"Wynn","year":"2009","journal-title":"Bone"},{"issue":"1","key":"2025100307131636400_bvaf148-B23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jc.2008-1662","article-title":"Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women","volume":"94","author":"Dawson-Hughes","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025100307131636400_bvaf148-B24","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/jbmr.2554","article-title":"Potassium bicarbonate supplementation lowers bone turnover and calcium excretion in older men and women: a randomized dose-finding trial","volume":"30","author":"Dawson-Hughes","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025100307131636400_bvaf148-B25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jbmr.1764","article-title":"Potassium citrate supplementation results in sustained improvement in calcium balance in older men and women","volume":"28","author":"Moseley","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"25","key":"2025100307131636400_bvaf148-B26","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJM199406233302502","article-title":"Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate","volume":"330","author":"Sebastian","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"2025100307131636400_bvaf148-B27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1210\/jc.2012-3099","article-title":"Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial","volume":"98","author":"Jehle","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025100307131636400_bvaf148-B28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","article-title":"Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO), international osteoporosis foundation (IOF), and international federation of clinical chemistry and laboratory medicine (IFCC)","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025100307131636400_bvaf148-B29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025100307131636400_bvaf148-B30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"key":"2025100307131636400_bvaf148-B31","unstructured":"Supplemental Appendix: The Association of Bone-Related Biomarkers with Incident Hip Fracture: A Nested Case-Control Analysis in the Nurses\u2019 Health Study and Health Professionals Follow-up Study [Internet]. figshare. 2025. Accessed August 13, 2025. https:\/\/figshare.com\/articles\/figure\/Supplemental_Appendix_The_Association_of_Bone-Related_Biomarkers_with_Incident_Hip_Fracture_A_Nested_Case-Control_Analysis_in_the_Nurses_Health_Study_and_Health_Professionals_Follow-up_Study\/29906411\/1"},{"issue":"5","key":"2025100307131636400_bvaf148-B32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/oxfordjournals.aje.a114319","article-title":"Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women","volume":"123","author":"Colditz","year":"1986","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2025100307131636400_bvaf148-B33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference: understanding AIC and BIC in model selection","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociol Methods Res"},{"issue":"4","key":"2025100307131636400_bvaf148-B34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00109-024-02418-8","article-title":"Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases","volume":"102","author":"Martiniakova","year":"2024","journal-title":"J Mol Med"},{"issue":"1","key":"2025100307131636400_bvaf148-B35","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12891-019-2863-y","article-title":"A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls","volume":"20","author":"Liu","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"2025100307131636400_bvaf148-B36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5535\/arm.2018.42.3.441","article-title":"The changes of CTX, DPD, osteocalcin, and bone mineral density during the postmenopausal period","volume":"42","author":"Park","year":"2018","journal-title":"Ann Rehabil Med"},{"issue":"1","key":"2025100307131636400_bvaf148-B37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jbspin.2011.05.003","article-title":"Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis","volume":"79","author":"Biver","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"1","key":"2025100307131636400_bvaf148-B38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12891-022-05427-1","article-title":"Association of bone-related biomarkers with femoral neck bone strength","volume":"23","author":"Xia","year":"2022","journal-title":"BMC Musculoskelet Disord"},{"issue":"11","key":"2025100307131636400_bvaf148-B39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/GME.0000000000002257","article-title":"Correlation between bone mineral density and bone metabolic markers in postmenopausal women with osteoporotic fractures at different C-terminal telopeptide of type 1 collagen levels: a retrospective analysis study","volume":"30","author":"Zhu","year":"2023","journal-title":"Menopause"},{"key":"2025100307131636400_bvaf148-B40","doi-asserted-by":"crossref","first-page":"1013483","DOI":"10.3389\/fphar.2022.1013483","article-title":"Clinical application of the fracture risk assessment tool in the general population and its correlation with bone turnover markers","volume":"13","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025100307131636400_bvaf148-B41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bone.2015.11.005","article-title":"Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population","volume":"83","author":"Dai","year":"2016","journal-title":"Bone"},{"issue":"9","key":"2025100307131636400_bvaf148-B42","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00198-019-05043-1","article-title":"Biochemical markers of bone turnover and risk of incident hip fracture in older women: the cardiovascular health study","volume":"30","author":"Massera","year":"2019","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025100307131636400_bvaf148-B43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-022-00996-8","article-title":"Bone turnover marker profiling and fracture risk in older women: fracture risk from age 75 to 90","volume":"111","author":"Ivaska","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"2025100307131636400_bvaf148-B44","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2025100307131636400_bvaf148-B45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bonekey.2013.95","article-title":"Clinical utility of serum sclerostin measurements","volume":"2","author":"Clarke","year":"2013","journal-title":"Bonekey Rep"},{"issue":"2","key":"2025100307131636400_bvaf148-B46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025100307131636400_bvaf148-B47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025100307131636400_bvaf148-B48","doi-asserted-by":"crossref","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","article-title":"Association of circulating sclerostin levels with fat mass and metabolic disease\u2014related markers in Japanese postmenopausal women","volume":"97","author":"Urano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025100307131636400_bvaf148-B49","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1007\/s00068-022-02017-7","article-title":"Serum sclerostin levels in osteoporotic fracture patients","volume":"48","author":"Gorter","year":"2022","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"1","key":"2025100307131636400_bvaf148-B50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/jc.2013-3168","article-title":"Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-diabetes heart study","volume":"99","author":"Register","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025100307131636400_bvaf148-B51","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study","volume":"27","author":"Ardawi","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025100307131636400_bvaf148-B52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025100307131636400_bvaf148-B53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jbmr.1823","article-title":"Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study","volume":"28","author":"Szulc","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025100307131636400_bvaf148-B54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1530\/EJE-12-1074","article-title":"Serum sclerostin levels in men with idiopathic osteoporosis","volume":"168","author":"Lapauw","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025100307131636400_bvaf148-B55","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician's guide to prevention and treatment of osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025100307131636400_bvaf148-B56","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025100307131636400_bvaf148-B57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18110","article-title":"Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups","volume":"18","author":"Burch","year":"2014","journal-title":"Health Technology Assessment"},{"issue":"2","key":"2025100307131636400_bvaf148-B58","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.ajkd.2014.07.007","article-title":"Serum bicarbonate and bone mineral density in US adults","volume":"65","author":"Chen","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2025100307131636400_bvaf148-B59","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1210\/jc.2014-4166","article-title":"Arterialized venous bicarbonate is associated with lower bone mineral density and an increased rate of bone loss in older men and women","volume":"100","author":"Tabatabai","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025100307131636400_bvaf148-B60","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00198-019-05132-1","article-title":"Fracture-induced changes in biomarkers CTX, PINP, OC, and BAP\u2014a systematic review","volume":"30","author":"H\u00f8jsager","year":"2019","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025100307131636400_bvaf148-B61","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jor.22129","article-title":"Strongly enhanced levels of sclerostin during human fracture healing","volume":"30","author":"Sarahrudi","year":"2012","journal-title":"J Orthop Res"},{"issue":"11","key":"2025100307131636400_bvaf148-B62","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s40618-023-02082-8","article-title":"A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS","volume":"46","author":"Adami","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025100307131636400_bvaf148-B63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13697137.2021.1945027","article-title":"Fracture risk assessment by the FRAX model","volume":"25","author":"McCloskey","year":"2022","journal-title":"Climacteric"},{"issue":"11","key":"2025100307131636400_bvaf148-B64","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1359\/jbmr.070713","article-title":"Clinical risk factors for fractures in multi-ethnic women: the Women's health initiative","volume":"22","author":"Cauley","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025100307131636400_bvaf148-B65","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00198-011-1693-z","article-title":"Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status","volume":"23","author":"Looker","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025100307131636400_bvaf148-B66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1359\/jbmr.090706","article-title":"Prevalence and trends in low femur bone density among older US adults: NHANES 2005\u20132006 compared with NHANES III","volume":"25","author":"Looker","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025100307131636400_bvaf148-B67","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1111\/jgs.16785","article-title":"Bone mineral density in older U.S. Filipino, Chinese, Japanese, and white women","volume":"68","author":"Lo","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2025100307131636400_bvaf148-B68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ecl.2023.05.004","article-title":"Racial and ethnic disparities in metabolic bone disease","volume":"52","author":"Maldonado","year":"2023","journal-title":"Endocrinol Metab Clin North Am"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf148\/64237404\/bvaf148.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf148\/64237404\/bvaf148.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/10\/bvaf148\/64237404\/bvaf148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:13:34Z","timestamp":1759490014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf148\/8250743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,5]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf148","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,5]]},"article-number":"bvaf148"}}